Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195918 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Hal Chapman.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT05195918 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Hal Chapman. The registered enrollment target is 50 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05195918, a Phase 1 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Hal Chapman.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Conditions Studied
Interventions
- COMBINATION_PRODUCT EGCG 300 mg + Nintedanib
- COMBINATION_PRODUCT EGCG 300 mg + Pirfenidone
- COMBINATION_PRODUCT Placebo 2 capsules + Nintedanib or Pirfenidone
- COMBINATION_PRODUCT EGCG 600 mg + Nintedanib
- COMBINATION_PRODUCT EGCG 600 mg + Pirfenidone
Study Locations (7)
California
- UCSF Parnassus - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medicine - New York
Pennsylvania
- Temple University - Philadelphia
Virginia
- University of Virginia - Charlottesville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2026-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05195918
The ClinicalTrials.gov registry entry for NCT05195918 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is Hal Chapman, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 5 interventions - of which EGCG 300 mg + Nintedanib is the first listed.
NCT05195918 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT05195918 about?
NCT05195918 is a clinical study titled "Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients". The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
What is the current status of trial NCT05195918?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-08-24. Estimated completion is 2026-04-21.
What conditions does trial NCT05195918 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05195918?
The interventions under investigation include: EGCG 300 mg + Nintedanib (COMBINATION_PRODUCT), EGCG 300 mg + Pirfenidone (COMBINATION_PRODUCT), Placebo 2 capsules + Nintedanib or Pirfenidone (COMBINATION_PRODUCT), EGCG 600 mg + Nintedanib (COMBINATION_PRODUCT), EGCG 600 mg + Pirfenidone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05195918?
This trial is sponsored by Hal Chapman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195918 being conducted?
This trial has 7 study locations across California, Massachusetts, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.